Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet American College of Rheumatology (ACR) criteria for RA~2. Have active RA~3. ACR functional class I-III~4. Disease onset at \> 16 years of age~5. Disease duration of at least 6 months~6. Failure to one DMARD including methotrexate and anti-TNF alpha~Exclusion Criteria:~1. Pregnant or breastfeeding women~2. Inadequate bone marrow function~3. Current use of a DMARD within 4 weeks (or 5 half-lives, whichever is longer) of screening except for leflunomide which requires a specific wash-out~4. Any previous use of recombinant IL1-Ra~5. Current use of more than 1 non steroidal anti-inflammatory drug (NSAID) or change of dose of the NSAID within 4 weeks of baseline or NSAID use greater than the maximum recommended dose~6. Within 4 weeks before baseline, use of more than 10 mg/day of prednisone or equivalent or change in the dose of prednisone or equivalent, or having intra-articular corticosteroid injection or bolus intramuscular or intravenous treatment with corticosteroids (\>20 mg prednisone or equivalent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): masitinib (AB1010) 3 mg/kg/day
- 2 (Type: EXPERIMENTAL): masitinib (AB1010) 6 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).